Nanobiotix S.A. NBTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -552.76% | -608.19% | 56.14% | 57.29% | 74.05% |
| Total Depreciation and Amortization | 0.42% | 8.96% | -8.92% | -11.32% | 7.33% |
| Total Amortization of Deferred Charges | -- | -- | -42.86% | -45.45% | -- |
| Total Other Non-Cash Items | 239.33% | 251.16% | -74.47% | -75.14% | -609.06% |
| Change in Net Operating Assets | -369.54% | -392.40% | -371.87% | -364.74% | -85.67% |
| Cash from Operations | -6.98% | -16.06% | -27.49% | -24.15% | -214.58% |
| Capital Expenditure | -328.44% | -364.89% | -18.65% | -15.60% | 67.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 108.82% | 109.52% | 68.77% | 69.57% | -15.25% |
| Cash from Investing | -262.57% | -293.43% | 0.16% | 2.76% | 65.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 13.99% | 13.99% | -6.69% | -6.69% | -21.90% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 601.19% | 601.19% | -431.54% | -431.54% | 44.83% |
| Cash from Financing | 2,870.02% | 3,105.09% | 1,872.21% | 1,825.80% | -12.40% |
| Foreign Exchange rate Adjustments | 178.82% | 185.50% | 141.91% | 136.07% | -1,364.94% |
| Miscellaneous Cash Flow Adjustments | 0.00% | -20.00% | -- | -- | -- |
| Net Change in Cash | 384.82% | 409.01% | 257.46% | 253.33% | -146.51% |